Patient P-01368

Synthetic patientNBL-101 · Day 105 · 45–54 · F · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Unstable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

94%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 45 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 54 GI-04 recommended — GI Support Protocol GI-04
Day 55 Patient accepted — Started GI-04 in the companion
Day 63 GI symptom burden −24% vs expected — GI Support Protocol GI-04
Day 69 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 45.

Primary contributors, last 14 days

Nutritional resilience-16
GI instability+13
Inflammatory activity+7
Toxicity-5
Treatment adherence-3

What helped?

GI Support Protocol GI-04Day 54
Result: symptom burden −24%

LIFE OS recommendation

Dietary Support Protocol NP-02

59%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 61
Autonomic recovery ↑65
- WearableResting HR 80 bpm
- Wearable3,614 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 61 and rising
- WearableSleep 5.4 h, below personal baseline
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 27/100
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 59

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Intermediate metabolizer
Expected exposure

Microbiome

Shannon diversity 2.2 · butyrate capacity 27/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 50 ms
Sleep: 5.8 h
Steps: 3,542
Resting HR: 79 bpm

Daily log: GI score 61, nutritional resilience 30, adherence 42.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01360	47%	S14	GI-04	improved	52
P-01417	47%	S14	GI-04	improved	65
P-01311	44%	S14	ME-01	improved	49
P-01465	44%	S14	NP-02	improved	56
P-01539	44%	S14	GI-04	improved	43
P-01716	44%	S14	GI-04	improved	56
P-01842	44%	S14	NP-02	improved	55
P-01433	43%	S14	GI-04	improved	48
P-01494	43%	S14	GI-04	improved	42
P-01612	43%	S14	ME-01	improved	51
P-01675	43%	S14	NP-02	improved	38
P-01732	43%	S14	ME-01	improved	45